Skip to main content

Table 5 The details of follow-up studies

From: Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement

Case no. Surgery Histopathology Chemotherapy ROS1 detection CT imagine TKI start time Response Reexamination CT imagine Side effects
Patient 3 Video-assisted thoracic surgery (VATS) of the left upper lobe wedge resection Invasive mucinous adenocarcinoma with pleural invasion Pemetrexed, carboplatin IHC, FISH and qRT-PCR had proved he as ROS1 rearrangement. Fusion type: CD74-E6 The largest lesion in his left thoracic wall was approximate in size to 40.81 × 12.70 mm2 Crizotinib 250 mg bid from December 2014 February 2015, the lesion decreased to 26.66 × 11.69 mm2 in size October 2015, the largest lesion shrunk to 10.85 × 8.60 mm2 in size Tiredness and constipation
Patient 6 Lower right lobe radical resection; Biopsy under CT guidance Invasive adenocarcinoma with acinar predominant pattern Pematrexed, nadaplatin and bevacizumab IHC, FISH and qRT-PCR had proved she as ROS1 rearrangement. Fusion type: CD74-E6 The largest lesion was approximated in size to 36.25 × 36.25 mm2 on the pleura Crizotinib 250 mg bid from April 2014 May 2014, the largest lesion decreased to 11.02 × 8.59 mm2 in size October 2015, the largest lesion shrunk to 10.48 × 10.33 mm2 in size Edema in lower limbs, vomiting and tiredness
Patient 7 Biopsy under CT guidance Invasive adenocarcinoma with acinar pattern IHC and FISH had proved she as ROS1 rearrangement The largest lesion was approximate in size to 35.33 × 19.73 mm2 Crizotinib 250 mg bid from July 2014 September 2014, the lesion decreased to 26.97 × 15.12 mm2 in size November 2015, her largest lesion shrunk to 16.25 × 5.65 mm2 in size Tiredness